1 Clinical Trials?

Phase 1 clinical trials are the first stage of human testing in the drug development process. Often referred to as first-in-human (FIH) studies, they focus primarily on assessing a drug’s safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD).

Unlike Phase 0 trials, which use microdosing to gather early signals, Phase 1 studies involve ascending therapeutic doses and may involve either healthy volunteers or patients, depending on the therapeutic area (e.g., oncology often starts directly in patients).

Key Objectives of Phase 1 Trials

• Safety Profiling: Identify any adverse effects, toxicities, or serious reactions
• Determine Maximum Tolerated Dose (MTD): Establish the highest safe dose
• Characterize Pharmacokinetics: How the body absorbs, distributes, metabolizes, and eliminates the drug
• Assess Pharmacodynamics: Explore the drug’s biological effect (if measurable)

The goal is not to test efficacy, but rather to generate data that supports safe progression to Phase 2 efficacy studies.

Who Participates in Phase 1 Studies?

• Healthy Volunteers: Common in non-cytotoxic drugs, such as cardiovascular, CNS, or metabolic agents
• Patients: In oncology, rare diseases, and high-risk therapeutics, patients with the target condition are enrolled

Typical Phase 1 trials enroll 20 to 100 participants across multiple dose levels.

Types of Phase 1 Study Designs

• Single Ascending Dose (SAD): Participants receive single increasing doses of the drug to assess safety and PK
• Multiple Ascending Dose (MAD): Participants receive repeated doses over time to evaluate accumulation and steady-state PK
• Food Effect Studies: Evaluate how food intake alters drug absorption
• Bioavailability and Bioequivalence Studies: Compare formulations or delivery methods

Regulatory Requirements for Phase 1 Trials

United States – FDA

• Phase 1 requires an Investigational New Drug (IND) application submitted under 21 CFR Part 312
• Includes preclinical toxicology, CMC (chemistry, manufacturing, and controls), and proposed clinical protocol

European Union – EMA

• Requires a Clinical Trial Application (CTA) submitted through the Clinical Trials Information System (CTIS)
• Follows ICH E6 (GCP) and ICH M3(R2) for risk-based evaluation

India – CDSCO

• Requires Form CT-04 (application) and Form CT-06 (approval) under New Drugs and Clinical Trials Rules
• Studies must be registered with CTRI and approved by Institutional Ethics Committees

Globally, adherence to ICH-GCP, GLP (for preclinical), and GMP (for IMP manufacturing) is required.

Preclinical Requirements Before Phase 1

• GLP-compliant toxicology studies in at least two species (rodent + non-rodent)
• Genotoxicity and safety pharmacology data
• Pharmacokinetic and metabolism studies to understand systemic exposure

These data establish the NOAEL (No Observed Adverse Effect Level) and support the calculation of a safe starting dose using MABEL or allometric scaling.

Importance of Phase 1 Trials in Clinical Development

Phase 1 trials are the foundation of all subsequent clinical testing. They answer critical questions like:

• Is the drug safe to proceed to larger studies?
• How does it behave in the human body compared to animal models?
• What is the right dose to carry forward?

Well-executed Phase 1 studies can de-risk Phase 2/3 trials and support early licensing, fast-track, or orphan drug applications.

Challenges in Phase 1 Studies

• Unexpected toxicities or severe adverse events
• Non-linear PK behavior complicating dose predictions
• Regulatory holds due to incomplete or poor-quality preclinical data

These challenges underscore the need for rigorous planning, modeling, and cross-functional team coordination.

Conclusion

Phase 1 trials represent the critical transition from laboratory research to human application. They form the gateway to every successful drug approval. With the right design, regulatory foundation, and scientific insight, Phase 1 trials unlock the potential of innovation—safely, ethically, and efficiently.